Smaller drugmakers beat Big Pharma in partnering popularity contest

Big Pharma companies aren't the most popular partners for biotechs looking to out-license products, a Boston Consulting survey found. Even top-scoring GlaxoSmithKline ($GSK) has moved down in the ranks, as smaller drugmakers like Celgene ($CELG) and Novo Nordisk ($NVO) moved up to first and second place. Report

Suggested Articles

Dupixent has been posting strong sales growth for Sanofi, and now the drugmaker has a third FDA indication to keep the momentum going.

Novartis has found itself caught up in a controversy about ingredients shipped to Syria that critics say could have been used to make sarin gas. 

AbbVie made a major splash Tuesday with its proposed $63 billion buyout of Allergan. But analysts and investors were hardly impressed.